In an interview conducted at the European Hematology Association Congress 2022 held in Vienna, Austria, Timothy Hughes, MD, of the South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, comments on a study designed to compare nilotinib therapy with a switch approach with nilotinib plus imatinib for first-line treatment of patients with chronic myeloid leukemia. The interim analysis reveals a significant benefit to starting patients with nilotinib compared with starting on imatinib and switching to nilotinib.